Mayzent (siponimod)

pCPA File Number: 21280

Negotiation Status:

Concluded with an LOI

Indication(s):

Secondary Progressive Multiple Sclerosis (SPMS)

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

SR0631-000

pCPA Engagement Letter Issued:

2021-04-27

Negotiation Process Concluded:

2021-10-22